Cargando…

Cytomegalic hepatitis in a patient receiving omalizumab

Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body fluids. The primary infection is usually asymptomatic in the immunocompetent host and it is common among adolescents and young adults. The symptomatic form appears, in the majority of cases, as a mononuc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, R., Valente, C., Ferreira, E., Serra, J.E., da Cunha, J. Saraiva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995387/
https://www.ncbi.nlm.nih.gov/pubmed/27583207
http://dx.doi.org/10.1016/j.idcr.2016.08.001
_version_ 1782449464024236032
author Gonçalves, R.
Valente, C.
Ferreira, E.
Serra, J.E.
da Cunha, J. Saraiva
author_facet Gonçalves, R.
Valente, C.
Ferreira, E.
Serra, J.E.
da Cunha, J. Saraiva
author_sort Gonçalves, R.
collection PubMed
description Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body fluids. The primary infection is usually asymptomatic in the immunocompetent host and it is common among adolescents and young adults. The symptomatic form appears, in the majority of cases, as a mononucleosis syndrome with full recovery without specific treatment. We report a case of a 25 years old woman who presented with hepatitis due to CMV infection and history of omalizumab administration one month earlier. This recombinant monoclonal antibody is used to control refractory asthma and chronic spontaneous urticarial as it inhibits human IgE. Despite that, the long course of the disease lead us to initiate treatment with valganciclovir. The improvement after that was rapid and complete.
format Online
Article
Text
id pubmed-4995387
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-49953872016-08-31 Cytomegalic hepatitis in a patient receiving omalizumab Gonçalves, R. Valente, C. Ferreira, E. Serra, J.E. da Cunha, J. Saraiva IDCases Case Report Cytomegalovirus is a double stranded DNA virus that can be present in nearly all organs and body fluids. The primary infection is usually asymptomatic in the immunocompetent host and it is common among adolescents and young adults. The symptomatic form appears, in the majority of cases, as a mononucleosis syndrome with full recovery without specific treatment. We report a case of a 25 years old woman who presented with hepatitis due to CMV infection and history of omalizumab administration one month earlier. This recombinant monoclonal antibody is used to control refractory asthma and chronic spontaneous urticarial as it inhibits human IgE. Despite that, the long course of the disease lead us to initiate treatment with valganciclovir. The improvement after that was rapid and complete. Elsevier 2016-08-11 /pmc/articles/PMC4995387/ /pubmed/27583207 http://dx.doi.org/10.1016/j.idcr.2016.08.001 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Gonçalves, R.
Valente, C.
Ferreira, E.
Serra, J.E.
da Cunha, J. Saraiva
Cytomegalic hepatitis in a patient receiving omalizumab
title Cytomegalic hepatitis in a patient receiving omalizumab
title_full Cytomegalic hepatitis in a patient receiving omalizumab
title_fullStr Cytomegalic hepatitis in a patient receiving omalizumab
title_full_unstemmed Cytomegalic hepatitis in a patient receiving omalizumab
title_short Cytomegalic hepatitis in a patient receiving omalizumab
title_sort cytomegalic hepatitis in a patient receiving omalizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995387/
https://www.ncbi.nlm.nih.gov/pubmed/27583207
http://dx.doi.org/10.1016/j.idcr.2016.08.001
work_keys_str_mv AT goncalvesr cytomegalichepatitisinapatientreceivingomalizumab
AT valentec cytomegalichepatitisinapatientreceivingomalizumab
AT ferreirae cytomegalichepatitisinapatientreceivingomalizumab
AT serraje cytomegalichepatitisinapatientreceivingomalizumab
AT dacunhajsaraiva cytomegalichepatitisinapatientreceivingomalizumab